– USA, NJ – Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, today announced the appointment of current EVP, global services, and CFO, Rob Davis to its Board of Directors as CEO, effective July 1, 2021, succeeding Ken Frazier who will retire as CEO, effective June 30, 2021, and will continue to serve on the board of directors as executive chairman, for a transition period.
Mr. Davis will become president of Merck, effective April 1, 2021, at which time the company’s operating divisions—Human Health, Animal Health, Manufacturing, and Merck Research Laboratories—will begin reporting to him.
“The board and I are delighted that Rob will serve as Merck’s next CEO,” said Ken Frazier. “He has deep knowledge of our company and industry and has been a valued strategic thought partner to me and the Merck senior management team as well as a highly capable finance leader. Rob has been instrumental in helping Merck take the right actions to adapt to the changing healthcare environment while remaining committed to investing in the scientific innovation that we expect will drive our future growth. His intellect and proven ability to define and articulate strategies that can be translated into clear and focused operational plans that lead to successful execution are also critical attributes. Rob personifies the values and integrity that are essential for a leader of Merck. I am confident that he has the strategic and leadership skills necessary to ensure that the company remains fully committed to its core mission of translating cutting-edge science into products and services that save and improve lives while simultaneously adopting new business and operating models that will unlock future value through innovation, digital transformation, and efficiency.”
Les Brun, lead independent director, said, “On behalf of the entire Merck board, I thank Ken for his strong and highly principled leadership and his commitment to the company’s core values of scientific excellence, business integrity, patient focus, and respect for all people. Ken’s vision and courage to make difficult changes within Merck, while steadfastly investing in research and development, have positioned Merck well for sustainable future growth. Under Ken’s leadership, Merck has delivered many innovative lifesaving medicines and vaccines, including KEYTRUDA, GARDASIL 9, and BRIDION, and also focused on other key growth drivers, such as Lynparza, Lenvima, and animal health to create long-term value for its shareholders and other stakeholders.
Ken’s belief in the importance of a strong, values-based culture, and his ability to attract and retain the best talent, will stand as an enduring testament to his concern and care for the people whose skill and commitment will be critical to Merck’s continued success. These characteristics and accomplishments, coupled with his principled stances on broader public issues, especially those involving intolerance and injustice, make his planned retirement felt so personally by every member of the board.”
Mr. Brun added, “During our succession planning process the board has had an opportunity to witness Rob’s substantial contributions to the company and the leadership team. He is the right person to lead Merck into the future. We have tremendous confidence in Rob’s ability to continue to foster innovation and to team with Dean Li, president of Merck Research Laboratories, to drive scientific excellence into the future. We are particularly pleased that Ken will continue as executive chairman to work with Rob and Dean to ensure a smooth transition for the company.”
“It has been a privilege to serve as Merck’s CEO for the past decade and to work with the most dedicated and talented employees and management team in the industry,” said Mr. Frazier. “As executive chairman, I look forward to collaborating with Rob and our board of directors to help Merck achieve even higher levels of success.”
About Robert Davis
Mr. Davis joined Merck as CFO in 2014. In 2016 his role was expanded to include the company’s global support functions, which encompass corporate business development, investor relations, information technology, procurement, real estate operations, and corporate strategy.
Before joining Merck, Mr. Davis was corporate VP and president of Baxter’s Medical Products business, where he oversaw the successful integration of that company’s Global Medication Delivery and Renal businesses into a single organization encompassing commercial operations, manufacturing, and R&D, laying the foundation for sustained growth and a solid R&D pipeline still delivering value today. Before that, Mr. Davis served as corporate VP and president of Baxter’s Renal business, as corporate VP and CFO from May 2006 through May 2010, and as treasurer from 2004 through May 2006. Mr. Davis previously spent more than 14 years at Eli Lilly and Company.
Mr. Davis serves on the board of directors of Duke Energy Corporation and is a member of its compensation and finance committees. Also, he is a board member of Project Hope, a non-profit organization focused on empowering health care workers to deliver expert care when and where it is needed most.
Mr. Davis said, “I am honored to be appointed the next CEO of Merck. I thank the board and Ken for their confidence in me. I plan to continue Ken’s focus on innovation as we aspire to be the premier research-intensive biopharmaceutical company. This will be a year of great change both for the company and for our industry. As we work through the pandemic, we will continue to focus on the important work of bringing our medicines and vaccines to those who need them. Merck will not waiver in its role of searching for and developing medically necessary products to improve people’s lives throughout the world.”
Mr. Davis received his J.D. from Northwestern University School of Law, his M.B.A. from Northwestern University’s Kellogg Graduate School of Management, and his bachelor’s degree in finance from Miami University.
For 130 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs, and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as we aspire to be the premier research-intensive biopharmaceutical company in the world.
For more information: https://www.merck.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.